IONETIX is a leading molecular imaging diagnostics and therapeutics company focused on providing physicians and patients access to N-13 Ammonia. Used by a growing number of academic institutions, N-13 Ammonia is rapidly changing the standard of excellence for myocardial perfusion in cardiac PET imaging. By combining our expertise, experience, and cutting-edge infrastructure solution, IONETIX creates new pathways for bringing N-13 Ammonia into your practice. Our innovative dose service model eliminates the up-front expense and provides the support needed to launch a successful cardiac PET program, while helping to establish a brand-differentiating service that keeps patients close and drives referrals. For more information, visit: www.ionetix.com or visit our booth. #219
N-13 Ammonia provides:
• Improved clinical accuracy
• Superior image quality
• Less roll off at higher flows
• Better extraction
• Fewer correction factors
N-13 Ammonia paves the way to better diagnostics with a low positron range, excellent extraction and retention, high sensitivity and overall accuracy for detecting CAD. The result is better risk classification and overall patient management.
Fiechter et al., J Nucl Med 2012; 53: 1230-1234